細胞治療市場規模、佔有率及成長分析（按技術、類型、細胞類型、細胞來源、應用、最終用戶和地區）—2025 年至 2032 年產業預測

2023 年細胞治療市場規模價值 69 億美元，預計將從 2024 年的 83.8 億美元成長到 2032 年的 398.1 億美元，預測期間（2025-2032 年）的複合年成長率為 21.5%。

全球細胞治療市場正在經歷顯著成長，主要原因是退化性疾病和慢性疾病的日益流行，這些疾病需要創新的治療方法。幹細胞研究和再生醫學的進步正在擴大治療前景並為疾病管理提供新的途徑。對細胞研究的大量投資進一步推動了新型治療方法的發展，為行業相關人員創造了豐厚的利潤機會。個人化醫療的需求不斷成長，即根據患者的個人情況量身定做治療方案，這也促進了人們對細胞療法的興趣日益濃厚。然而，一些挑戰可能會阻礙市場成長。開發和生產細胞療法的成本高昂，令人難以承受，尤其是對於較小的製藥公司和研究機構。此外，免疫排斥的風險仍然令人擔憂，需要嚴格的測試和檢驗以確保患者的安全。複雜而嚴格的監管核准流程進一步延遲了新治療方法的商業化，並對市場進入構成了障礙。儘管面臨這些挑戰，但在持續研究、技術進步以及對慢性和退化性疾病有效治療的迫切需求的推動下，細胞治療市場預計在未來幾年將大幅擴張。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

細胞治療市場規模：依技術及複合年成長率（2025-2032）

• 市場概覽
• 體細胞技術
• 細胞永生化技術
• 病毒載體技術
• 基因組編輯技術
• 細胞可塑性技術
• 3D技術

細胞治療市場規模（按類型及複合年成長率） (2025-2032)

• 市場概覽
• 自體移植
• 同種異體

細胞治療市場規模（按細胞類型和複合年成長率） (2025-2032)

• 市場概覽
• 幹細胞
• 非幹細胞

細胞治療市場規模：依細胞來源及複合年成長率（2025-2032）

• 市場概覽
• iPSCs
• 骨髓
• 臍帶血衍生細胞
• 脂肪組織
• 神經幹細胞

細胞治療市場規模：按應用和複合年成長率（2025-2032）

• 市場概覽
• 肌肉骨骼
• 心血管
• 胃腸道
• 神經系統
• 腫瘤學
• 皮膚科
• 傷口和損傷
• 眼科
• 其他

細胞治療市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概覽
• 醫院和診所
• 再生醫學中心
• 診斷與研究中心
• 其他

細胞治療市場規模：按地區和複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Novartis AG（Switzerland）
• Gilead Sciences, Inc.（USA）
• Bristol Myers Squibb（USA）
• Johnson & Johnson（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Bluebird Bio, Inc.（USA）
• Mesoblast Limited（Australia）
• CRISPR Therapeutics（Switzerland）
• Adaptimmune Therapeutics plc（UK）
• Fate Therapeutics, Inc.（USA）
• Orchard Therapeutics plc（UK）
• Gamida Cell Ltd.（Israel）
• Allogene Therapeutics, Inc.（USA）
• Capricor Therapeutics, Inc.（USA）
• Vericel Corporation（USA）
• Mustang Bio, Inc.（USA）
• Atara Biotherapeutics, Inc.（USA）

結論和建議

Cell Therapy Market size was valued at USD 6.9 Billion in 2023 and is poised to grow from USD 8.38 Billion in 2024 to USD 39.81 Billion by 2032, growing at a CAGR of 21.5% during the forecast period (2025-2032).

The global cell therapy market is experiencing significant growth, primarily driven by the increasing prevalence of degenerative disorders and chronic diseases, which necessitate innovative treatment approaches. Advancements in stem cell research and regenerative medicine are expanding the therapeutic landscape, offering new avenues for disease management. Substantial investments in cell research are further propelling the development of novel therapies, creating lucrative opportunities for industry stakeholders. The rising demand for personalized medicine, which tailors treatments to individual patient profiles, is also contributing to the heightened interest in cell-based therapies. However, several challenges may impede market growth. The high costs associated with the development and manufacturing of cell therapies can be prohibitive, particularly for smaller pharmaceutical companies and research institutions. Additionally, the risk of immune rejection remains a concern, necessitating rigorous testing and validation to ensure patient safety. Complex and stringent regulatory approval processes can further delay the commercialization of new therapies, posing hurdles for market entrants. Despite these challenges, the cell therapy market is projected to expand significantly in the coming years, driven by continuous research, technological advancements, and the pressing need for effective treatments for chronic and degenerative diseases.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cell Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cell Therapy Market Segments Analysis

Global Cell Therapy Market is segmented by Technology, Type, Cell Type, Cell Source, Application, End-User and region. Based on Technology, the market is segmented into Somatic Cell Technology, Cell Immortalization Technology, Viral Vector Technology, Genome Editing Technology, Cell Plasticity Technology and Three-Dimensional Technology. Based on Type, the market is segmented into Autologous and Allogeneic. Based on Cell Type, the market is segmented into Stem Cell and Non-Stem Cell. Based on Cell Source, the market is segmented into iPSCs, Bone Marrow, Umbilical Cord Blood-Derived Cells, Adipose Tissues and Neural Stem Cell. Based on Application, the market is segmented into Musculoskeletal, Cardiovascular, Gastrointestinal, Neurological, Oncology, Dermatology, Wounds and Injuries, Ocular and Others. Based on End-User, the market is segmented into Hospitals and Clinics, Regenerative Medicine Centres, Diagnostic and Research Centres and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cell Therapy Market

The global surge in personalized medicine is significantly enhancing the adoption of innovative cell therapies, which are pivotal in addressing individual patient characteristics. By tailoring treatments to each person's unique genetic and molecular profile, these therapies improve efficacy and minimize adverse reactions. For instance, CAR T-cell therapy customizes a patient's immune cells to target specific cancer cells, leading to higher remission rates. This precision reduces the likelihood of treatment rejection and enhances overall patient outcomes. As personalized medicine continues to evolve, the integration of advanced cell therapies is expected to play a crucial role in developing more effective and safer treatments.

Restraints in the Cell Therapy Market

The risk of immune rejection significantly hampers the growth potential of the cell therapy market, particularly affecting the adoption of allogeneic treatments. In these therapies, donor cells are introduced into patients, but the recipient's immune system may recognize these cells as foreign, leading to their elimination. This immune response not only diminishes the therapeutic efficacy but also poses challenges in developing universally compatible cell therapies. Consequently, addressing immune rejection is crucial for advancing the widespread application of allogeneic cell therapies.

Market Trends of the Cell Therapy Market

The global incidence of cancer has risen substantially, intensifying the demand for innovative treatments. Chimeric Antigen Receptor T-cell (CAR-T) therapy, an emerging form of immunotherapy, has shown promise in targeting specific cancer cells by reprogramming a patient's own T-cells. This personalized approach enhances treatment efficacy and reduces the likelihood of adverse effects. The CAR-T cell therapy market is projected to grow significantly, with estimates suggesting a rise from USD 7.31 billion in 2024 to USD 188.84 billion by 2034, reflecting a compound annual growth rate (CAGR) of 36.8% during 2025-2034. Pharmaceutical companies are increasingly investing in CAR-T therapies to expand their portfolios and meet the growing demand for effective cancer treatments. For instance, AstraZeneca's recent acquisition of EsoBiotec, a biotech firm specializing in in-vivo CAR-T cell therapies, underscores the industry's commitment to advancing cell therapy innovations. By aligning with this trend, companies can enhance their market presence and contribute to the development of novel cancer therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Cell Therapy Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Somatic Cell Technology
• Cell Immortalization Technology
• Viral Vector Technology
• Genome Editing Technology
• Cell Plasticity Technology
• Three-Dimensional Technology

Global Cell Therapy Market Size by Type & CAGR (2025-2032)

• Market Overview
• Autologous
• Allogeneic

Global Cell Therapy Market Size by Cell Type & CAGR (2025-2032)

• Market Overview
• Stem Cell
• Non-Stem Cell

Global Cell Therapy Market Size by Cell Source & CAGR (2025-2032)

• Market Overview
• iPSCs
• Bone Marrow
• Umbilical Cord Blood-Derived Cells
• Adipose Tissues
• Neural Stem Cell

Global Cell Therapy Market Size by Application & CAGR (2025-2032)

• Market Overview
• Musculoskeletal
• Cardiovascular
• Gastrointestinal
• Neurological
• Oncology
• Dermatology
• Wounds and Injuries
• Ocular
• Others

Global Cell Therapy Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals and Clinics
• Regenerative Medicine Centres
• Diagnostic and Research Centres
• Others

Global Cell Therapy Market Size & CAGR (2025-2032)

• North America (Technology, Type, Cell Type, Cell Source, Application, End-User)
  • US
  • Canada
• Europe (Technology, Type, Cell Type, Cell Source, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Technology, Type, Cell Type, Cell Source, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Technology, Type, Cell Type, Cell Source, Application, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Technology, Type, Cell Type, Cell Source, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mesoblast Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptimmune Therapeutics plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fate Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orchard Therapeutics plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gamida Cell Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allogene Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Capricor Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vericel Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mustang Bio, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atara Biotherapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations